Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 391 - 400 of 1165

Uceris (budesonide)

Status:

Concluded with an LOI

Manufacturer:

Bausch Health, Canada Inc.

Indication:

Active mild to moderate distal ulcerative colitis

Last updated February 2, 2024

Wezlana (ustekinumab)

Status:

Concluded with an LOI

Manufacturer:

Amgen Canada Inc.

Indication:

Multiple Indications

Last updated January 25, 2024

Skyrizi (risankizumab)

Status:

Concluded with an LOI

Manufacturer:

AbbVie Corporation

Indication:

Moderately to severely active Crohn's disease in adults

Last updated January 24, 2024

Xydalba (dalbavancin)

Status:

Concluded with an LOI

Manufacturer:

Paladin Labs Inc.

Indication:

Acute bacterial skin and skin structure infections

Last updated January 23, 2024

Benlysta (belimumab)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Active lupus nephritis

Last updated January 18, 2024

Benlysta (belimumab)

Status:

Concluded with an LOI

Manufacturer:

GlaxoSmithKline Inc.

Indication:

Systemic lupus erythematosus

Last updated January 18, 2024

Empaveli (pegcetacoplan)

Status:

Concluded with an LOI

Manufacturer:

Sobi Canada Inc.

Indication:

Paroxysmal nocturnal hemoglobinuria (PNH) in adult patients who have an inadequate response to, or are intolerant of, a C5 inhibitor

Last updated January 17, 2024

Perjeta (pertuzumab)

Status:

Concluded without agreement

Manufacturer:

Hoffmann-La Roche Ltd.

Indication:

Breast cancer, Locally advanced, inflammatory, or early stage HER2-positive (either 2 cm in diameter or node positive), for neoadjuvant treatment of patients (in combination with trastuzumab and chemotherapy)

Last updated December 21, 2023

Rybelsus (semaglutide)

Status:

Concluded with an LOI

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated December 17, 2023

Ozempic (semaglutide)

Status:

Concluded with an LOI

Manufacturer:

Novo Nordisk Canada Inc.

Indication:

Diabetes Mellitus, Type 2

Last updated December 17, 2023

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 38
  • Page 39
  • Current page 40
  • Page 41
  • Page 42
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use